VAXX Stock Overview
A biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vaxxinity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0052 |
| 52 Week High | US$1.05 |
| 52 Week Low | US$0.000001 |
| Beta | -17.68 |
| 1 Month Change | 5,100.00% |
| 3 Month Change | 2,500.00% |
| 1 Year Change | -99.35% |
| 3 Year Change | -99.91% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Shareholder Returns
| VAXX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 225.0% | 0.2% | -0.2% |
| 1Y | -99.3% | -4.7% | 25.8% |
Return vs Industry: VAXX underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: VAXX underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| VAXX volatility | |
|---|---|
| VAXX Average Weekly Movement | 3,466.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VAXX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VAXX's weekly volatility has decreased from 5922% to 3467% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 61 | Mei Hu | www.vaxxinity.com |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial.
Vaxxinity, Inc. Fundamentals Summary
| VAXX fundamental statistics | |
|---|---|
| Market cap | US$659.09k |
| Earnings (TTM) | -US$56.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VAXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAXX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.93m |
| Earnings | -US$56.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 113.1% |
How did VAXX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 09:03 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaxxinity, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Geoffrey Meacham | BofA Global Research |
| Roger Song | Jefferies LLC |